Abstract

Botulinum toxin type A(BTX-A), a potent neurotoxin that reversibly blocks presynaptic acetylcholine release, has been applied successfully to treat facial spastic conditions such as blepharospasm, strabismus and cervical dystonia. Since the first reported application in dentistry in 1994, BTX-A has been used with great success to use in the orofacial region to help treat masticatory and facial muscle spasm, hypertrophy of the masticatory muscles, severe bruxism, temporomandibular pain and orofacial neuropathic pain. This review addresses the application of BTX-A in clinical dentistry that expands the indication recently.